Pharma Scope 3 in India: When Carbon Credits Work and When Supplier Engagement Wins
Indian pharmaceutical companies can usually cut their Scope 1 and 2 emissions with a handful of projects: efficient boilers, renewable power, solvent recovery. Scope 3 is harder. It sits in suppliers' plants, in logistics networks and in the products patients use. This post explains where carbon credits are a legitimate tool for that gap and where supplier engagement does more work per rupee.
Why pharma Scope 3 is different
Pharma is not one of the sectors with notified or drafted targets under India's Carbon Credit Trading Scheme. The nine sectors in the latest ICAP summary are aluminium, cement, chlor-alkali, pulp and paper, iron and steel, fertiliser, petroleum refining, petrochemicals and textiles. So there is no compliance obligation pushing a pharma buyer towards credits. Every purchase is voluntary, which means the buyer, not a regulator, has to defend its quality and its purpose.
The Scope 3 profile also differs from most manufacturers. The main hotspots are usually:
Purchased goods and services (Category 1): active pharmaceutical ingredients, intermediates, solvents and packaging, often from energy-intensive chemical suppliers.
Upstream transport (Category 4): temperature-controlled freight and air shipments of finished formulations.
Waste (Category 5): solvent and hazardous-waste incineration, which is process-specific.
Use of sold products (Category 11): relevant mainly for products such as metered-dose inhalers, whose propellants have a high warming potential.
The mix differs by business model. An API manufacturer's inventory tends to be dominated by solvents, reagents and energy, while a formulations company's is dominated by bought-in ingredients and packaging. Our guide to all 15 Scope 3 categories explains how to confirm which of these are material for your product mix before you choose a response.
Where supplier engagement beats credits
Category 1 is usually the largest block, and it is where credits are the weakest answer. The emissions come from named suppliers with named processes. Asking your top API and intermediate suppliers for primary data, setting a switch-to-renewables expectation in contracts and sharing abatement costs will reduce your inventory. A credit does not. It compensates for emissions that are still being released.
This is the logic behind insetting: investing inside your own value chain so the reduction shows up in your own footprint. We compare the two approaches in insetting versus offsetting for Indian companies. For pharma, a sensible rule is to engage suppliers first on any hotspot where you buy a meaningful share of a supplier's output, because you have commercial leverage there.
Where credits legitimately fit
Credits make sense for the residual: emissions you cannot yet remove or influence, such as long-tail logistics, employee commuting and business travel, or a short-term gap on the way to a Science Based Targets commitment. Four conditions keep that use defensible:
Report gross emissions first and show credits as a separate line, never netted silently against your inventory.
Buy credits from Verra or Gold Standard registered projects, and ask for the project's additionality and permanence evidence.
Match the project type to the risk. Removals, such as ARR and biochar, suit long-lived residuals; avoidance projects suit near-term, lower-cost needs.
Retire credits in your company's name, in the same year as the claim, and keep the serial numbers on file.
For the buying process, use our 27-question carbon credit RFP template. For tonnage planning, see how many credits a mid-size pharma company typically needs.
A practical split for a sustainability lead
A workable plan for a mid-size Indian drug maker has three layers. First, measure Scope 3 by category and rank hotspots by size and by how much influence you have. Second, put supplier engagement and renewable-power switching on the large, influenceable categories. Third, size credits only for the residual, and buy them gradually over several years rather than in one block. Revisit the split every year, because primary supplier data usually changes the hotspot ranking compared with spend-based estimates.
This ordering also protects you from greenwashing risk. Buyers and auditors, including those assessing your BRSR disclosures, increasingly look for evidence that reductions came first and credits came second. Our overview of decarbonisation routes for Indian pharma covers the Scope 1 and 2 side of the same plan.
Next step
If you are deciding how much of your Scope 3 gap credits should cover, our team can review your inventory, rank the hotspots and shortlist registry-verified projects through our carbon credits service. Contact C² to talk through your numbers.
Comments